Search

Your search keyword '"Lisa M. Becker"' showing total 4 results
4 results on '"Lisa M. Becker"'

1. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity

Author

Kathleen M. McAndrews, Dara P. Dowlatshahi, Jianli Dai, Lisa M. Becker, Janine Hensel, Laura M. Snowden, Jennifer M. Leveille, Michael R. Brunner, Kylie W. Holden, Nikolas S. Hopkins, Alexandria M. Harris, Jerusha Kumpati, Michael A. Whitt, J. Jack Lee, Luis L. Ostrosky-Zeichner, Ramesha Papanna, Valerie S. LeBleu, James P. Allison, and Raghu Kalluri

Subjects
COVID-19, Immunology, Medicine
Abstract

Evaluation of potential immunity against the novel severe acute respiratory syndrome (SARS) coronavirus that emerged in 2019 (SARS-CoV-2) is essential for health, as well as social and economic recovery. Generation of antibody response to SARS-CoV-2 (seroconversion) may inform on acquired immunity from prior exposure, and antibodies against the SARS-CoV-2 spike protein receptor binding domain (S-RBD) are speculated to neutralize virus infection. Some serology assays rely solely on SARS-CoV-2 nucleocapsid protein (N-protein) as the antibody detection antigen; however, whether such immune responses correlate with S-RBD response and COVID-19 immunity remains unknown. Here, we generated a quantitative serological ELISA using recombinant S-RBD and N-protein for the detection of circulating antibodies in 138 serial serum samples from 30 reverse transcription PCR–confirmed, SARS-CoV-2–hospitalized patients, as well as 464 healthy and non–COVID-19 serum samples that were collected between June 2017 and June 2020. Quantitative detection of IgG antibodies against the 2 different viral proteins showed a moderate correlation. Antibodies against N-protein were detected at a rate of 3.6% in healthy and non–COVID-19 sera collected during the pandemic in 2020, whereas 1.9% of these sera were positive for S-RBD. Approximately 86% of individuals positive for S-RBD–binding antibodies exhibited neutralizing capacity, but only 74% of N-protein–positive individuals exhibited neutralizing capacity. Collectively, our studies show that detection of N-protein–binding antibodies does not always correlate with presence of S-RBD–neutralizing antibodies and caution against the extensive use of N-protein–based serology testing for determination of potential COVID-19 immunity.

Published
2020
Full Text
View/download PDF

2. Tumor vessel co-option probed by single-cell analysis

Author

Steven Van Laere, Mieke Dewerchin, Lena-Christin Conradi, Peter Carmeliet, Anna Rita Cantelmo, Federico Taverna, Massimiliano Mazzone, Yonglun Luo, Stefan Vinckier, Stefaan J. Soenen, Nuphar Veiga, Tobias K. Karakach, Peter B. Vermeulen, Lucas Treps, Joanna Kalucka, Sébastien J. Dumas, Luc Dirix, Elda Meta, Shawez Khan, Vincent Geldhof, Guy Eelen, Laure-Anne Teuwen, Luc Schoonjans, Nadine V. Conchinha, Katerina Rohlenova, Lisa M. Becker, Anne Cuypers, Melissa García-Caballero, Laura P.M.H. de Rooij, Jacob Amersfoort, [Teuwen,LA, De Roji,PMH, Cuypers,A, Rohlenova,A, Dumas,SH, García-Caballero,M, Meta,E, Amersfoort,J, Taverna,F, Becker,LM, Veiga,N, Cantelmo,AR, Geldhof,V, Conchinha,NV, Kalucka,J, Treps,L, Conradi,LC, Khan,S, Karakach,TK, Vinckier,S, Schoonjans,L, Eelen,G, Dewerchin,M, Carmeliet,P] Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology (CCB), VIB, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium. [Teuwen,LA, Van Laere,S, Dirix,L, Vermeulen,P] Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Antwerp, Belgium. [Teuwen,LA, Vermeulen,P] Center for Oncological Research, University of Antwerp, Antwerp, Belgium. [Soenen,S] NanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. [Schoonjans,L, Carmeliet,P] State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, P.R. China. [Mazzone,M] Laboratory of Tumor Inflammation and Angiogenesis, CCB, VIB, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium. [Luo,Y] Department of Biomedicine, Aarhus University, Aarhus, Denmark. [Luo,Y] Lars Bolund Institute of Regenerative Medicine, BGI-Qingdao, Qingdao, P.R. China. [Luo,Y] BGI-Shenzhen, Shenzhen, China. [Luo,Y] China National GeneBank, BGI-Shenzhen, Shenzhen, P.R. China. [Carmeliet,P] Laboratory of Angiogenesis and Vascular Heterogeneity, Department of Biomedicine, Aarhus University, Aarhus, Denmark. [Rohlenova,K] Institute of Biotechnology of the Czech Academy of Sciences, Praha – za´ pad, Central Bohemia, Czechia. [García-Caballero,M] Department of Molecular Biology and Biochemistry, Faculty of Sciences, and IBIMA (Biomedical Research Institute of Málaga), University of Málaga, Andalucía Tech, Málaga, Spain. [Cantelmo,AR] Laboratory of Cell Physiology, Lille University, Villeneuve d’Ascq, France. [Kalucka,J] Aarhus Institute of Advanced Studies (AIAS), Department of Biomedicine, Aarhus University, Aarhus, Denmark. [Conradi,LC] Clinic of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany. [Khan,S] National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. [Karakach,TK] Bioinformatics Core Laboratory, Children’s Hospital Research Institute of Manitoba, Winnipeg, Canada. [Karakach,TK] Rady Faculty of Health Sciences, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba Canada., L.-A.T., L.D., S.V.L., and P.V. are supported by Fonds Oncologie Augustinus-Koning Boudewijnstichting and GZA Ziekenhuizen, A.C., K.R., N.V.C., L.P.M.H.d.R., and L.T. by the Fonds Wetenschappelijk Onderzoek (FWO), S.J.D. by a Marie Curie-IEF fellowship, V.G. by Strategisch Basisonderzoek FWO (SB-FWO), Y.L. by BGI-Research, Danish Research Council for Independent Research (DFF-1337-00128), Sapere Aude Young Research Talent Prize (DFF-1335–00763A), and Aarhus University Strategic Grant (AU-iCRISPR), and and P.C. by Methusalem funding (Flemish government), Fund for Scientific Research-Flanders (FWO-Vlaanderen), Foundation Against Cancer (2016-078), Kom op tegen Kanker (Stand up to Cancer, Flemish Cancer Society), European Research Council (ERC Proof of Concept grant ERC-713758 and Advanced ERC Research grant EU-ERC743074), and a NNF Laureate Research Grant from Novo Nordisk Foundation (NNF19OC0055802).

Subjects
Anatomy::Cells::Cells, Cultured::Cell Line::Cell Line, Tumor [Medical Subject Headings], 0301 basic medicine, Lung Neoplasms, Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Cytological Techniques::Single-Cell Analysis [Medical Subject Headings], Vascular permeability, Metastasis, Transcriptome, anti-angiogenic therapy, Mice, 0302 clinical medicine, Single-cell analysis, Neoplasms, Organisms::Eukaryota::Animals [Medical Subject Headings], Anatomy::Cells::Epithelial Cells::Endothelial Cells [Medical Subject Headings], Macrophage, Myeloid Cells, Biology (General), Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice::Mice, Inbred Strains::Mice, Inbred BALB C [Medical Subject Headings], Inbred BALB C, Mice, Inbred BALB C, Tumor, cancer cells, endothelial cells, macrophages, metastasis, pericytes, resistance, single-cell RNA sequencing, tumor angiogenesis, tumor vessel co-option, Animals, Cell Line, Tumor, Endothelial Cells, Female, Kidney Neoplasms, Macrophages, Pericytes, Single-Cell Analysis, Diseases::Neoplasms [Medical Subject Headings], 3. Good health, Metástasis de la neoplasia, Pericitos, Anatomy::Cells::Pericytes [Medical Subject Headings], Cell type, QH301-705.5, Anatomy::Cells::Myeloid Cells [Medical Subject Headings], Biology, Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [Medical Subject Headings], General Biochemistry, Genetics and Molecular Biology, Cell Line, 03 medical and health sciences, medicine, Macrófagos, Inductores de la angiogénesis, Células endoteliales, Cancer, medicine.disease, 030104 developmental biology, Cancer cell, Cancer research, Human medicine, 030217 neurology & neurosurgery
Abstract

Tumor vessel co-option is poorly understood, yet it is a resistance mechanism against anti-angiogenic therapy (AAT). The heterogeneity of co-opted endothelial cells (ECs) and pericytes, co-opting cancer and myeloid cells in tumors growing via vessel co-option, has not been investigated at the single-cell level. Here, we use a murine AAT-resistant lung tumor model, in which VEGF-targeting induces vessel co-option for continued growth. Single-cell RNA sequencing (scRNA-seq) of 31,964 cells reveals, unexpectedly, a largely similar transcriptome of co-opted tumor ECs (TECs) and pericytes as their healthy counterparts. Notably, we identify cell types that might contribute to vessel co-option, i.e., an invasive cancer-cell subtype, possibly assisted by a matrix-remodeling macrophage population, and another M1-like macrophage subtype, possibly involved in keeping or rendering vascular cells quiescent. ispartof: CELL REPORTS vol:35 issue:11 ispartof: location:United States status: published

Published
2021
Full Text
View/download PDF

3. Endothelial cell plasticity at the single-cell level

Author

Peter Carmeliet, Lisa M. Becker, Anne Cuypers, and Alessandra Pasut

Subjects
0301 basic medicine, Cancer Research, Endothelium, Physiology, Angiogenesis, Endothelial cells, Clinical Biochemistry, Neovascularization, Physiologic, Disease, VASCULAR ENDOTHELIUM, Biology, INTUSSUSCEPTIVE ANGIOGENESIS, medicine.disease_cause, Single-cell analyses, TUMOR ANGIOGENESIS, 03 medical and health sciences, 0302 clinical medicine, medicine, Animals, Humans, HETEROGENEITY, Tissue repair, Gene, Pathological, GENE-EXPRESSION, TRANSCRIPTOME ATLAS, Original Paper, Science & Technology, PROGENITORS, Neovascularization, Pathologic, VESSEL NORMALIZATION, Phenotype, Cell biology, Endothelial stem cell, 030104 developmental biology, medicine.anatomical_structure, Metabolism, Peripheral Vascular Disease, 030220 oncology & carcinogenesis, Tumorigenesis, Cardiovascular System & Cardiology, Endothelium, Vascular, Carcinogenesis, Life Sciences & Biomedicine, STEM-CELLS
Abstract

The vascular endothelium is characterized by a remarkable level of plasticity, which is the driving force not only of physiological repair/remodeling of adult tissues but also of pathological angiogenesis. The resulting heterogeneity of endothelial cells (ECs) makes targeting the endothelium challenging, no less because many EC phenotypes are yet to be identified and functionally inventorized. Efforts to map the vasculature at the single-cell level have been instrumental to capture the diversity of EC types and states at a remarkable depth in both normal and pathological states. Here, we discuss new EC subtypes and functions emerging from recent single-cell studies in health and disease. Interestingly, such studies revealed distinct metabolic gene signatures in different EC phenotypes, which deserve further consideration for therapy. We highlight how this metabolic targeting strategy could potentially be used to promote (for tissue repair) or block (in tumor) angiogenesis in a tissue or even vascular bed-specific manner. ispartof: ANGIOGENESIS vol:24 issue:2 pages:311-326 ispartof: location:Germany status: published

Published
2021
Full Text
View/download PDF

4. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity

Author

Michael R. Brunner, J. Jack Lee, Jianli Dai, Raghu Kalluri, Michael A. Whitt, Jennifer M. Leveille, Kylie W. Holden, Alexandria M. Harris, Dara P. Dowlatshahi, Luis Ostrosky-Zeichner, Jerusha Kumpati, Laura M. Snowden, Nikolas S. Hopkins, Ramesha Papanna, Kathleen M. McAndrews, James P. Allison, Lisa M. Becker, Valerie S. LeBleu, and Janine Hensel

Subjects
0301 basic medicine, Male, Research & Experimental Medicine, medicine.disease_cause, Antibodies, Viral, Serology, 0302 clinical medicine, COVID-19 Testing, Outcome Assessment, Health Care, Coronavirus, biology, General Medicine, Middle Aged, Acquired immune system, Medicine, Research & Experimental, Seroconversion, 030220 oncology & carcinogenesis, Spike Glycoprotein, Coronavirus, Medicine, Female, Antibody, Coronavirus Infections, Life Sciences & Biomedicine, Research Article, Protein Binding, Immunology, Adaptive immunity, Pneumonia, Viral, Sensitivity and Specificity, 03 medical and health sciences, Betacoronavirus, Immune system, Antigen, Immunity, medicine, Humans, Serologic Tests, Nucleocapsid, Pandemics, Science & Technology, Clinical Laboratory Techniques, SARS-CoV-2, COVID-19, Virology, Antibodies, Neutralizing, 030104 developmental biology, biology.protein, RESPONSES
Abstract

Evaluation of potential immunity against the novel severe acute respiratory syndrome (SARS) coronavirus that emerged in 2019 (SARS-CoV-2) is essential for health, as well as social and economic recovery. Generation of antibody response to SARS-CoV-2 (seroconversion) may inform on acquired immunity from prior exposure, and antibodies against the SARS-CoV-2 spike protein receptor binding domain (S-RBD) are speculated to neutralize virus infection. Some serology assays rely solely on SARS-CoV-2 nucleocapsid protein (N-protein) as the antibody detection antigen; however, whether such immune responses correlate with S-RBD response and COVID-19 immunity remains unknown. Here, we generated a quantitative serological ELISA using recombinant S-RBD and N-protein for the detection of circulating antibodies in 138 serial serum samples from 30 reverse transcription PCR–confirmed, SARS-CoV-2–hospitalized patients, as well as 464 healthy and non–COVID-19 serum samples that were collected between June 2017 and June 2020. Quantitative detection of IgG antibodies against the 2 different viral proteins showed a moderate correlation. Antibodies against N-protein were detected at a rate of 3.6% in healthy and non–COVID-19 sera collected during the pandemic in 2020, whereas 1.9% of these sera were positive for S-RBD. Approximately 86% of individuals positive for S-RBD–binding antibodies exhibited neutralizing capacity, but only 74% of N-protein–positive individuals exhibited neutralizing capacity. Collectively, our studies show that detection of N-protein–binding antibodies does not always correlate with presence of S-RBD–neutralizing antibodies and caution against the extensive use of N-protein–based serology testing for determination of potential COVID-19 immunity., Detection of SARS-CoV-2 nucleocapsid protein binding antibodies does not always correlate with the presence of spike protein receptor binding domain neutralizing antibodies.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results